Inclisiran dosing
Pro Research Analysisby 
Searched over 200M research papers for "inclisiran dosing"
Inclisiran Dosing Schedule and Administration
Inclisiran is a small interfering RNA (siRNA) therapy that targets PCSK9 to lower LDL cholesterol. The standard dosing regimen for inclisiran is an initial subcutaneous injection, followed by a second dose at 3 months, and then maintenance injections every 6 months thereafter. This twice-yearly dosing schedule is designed to provide sustained LDL cholesterol reduction and improve patient adherence compared to more frequent dosing regimens required by other lipid-lowering therapies 1367.
Efficacy of Different Inclisiran Dosing Regimens
Clinical trials have evaluated various dosing strategies, including single and double initial doses at different strengths (100 mg, 200 mg, 300 mg, and 500 mg). The most effective and commonly used regimen is 300 mg administered at baseline, 3 months, and then every 6 months. This approach has shown robust and durable reductions in LDL cholesterol and PCSK9 levels, with LDL cholesterol reductions of up to 52.6% at 180 days and sustained effects for at least 4 years 3456+1 MORE. The 300 mg dose consistently provided the greatest and most sustained lipid-lowering effects across diverse patient populations, including those with high cardiovascular risk and familial hypercholesterolemia 3689.
Missed Dose Management
If a scheduled inclisiran dose is missed by less than 3 months, the injection should be administered as soon as possible, and the regular dosing schedule should be resumed. If the dose is missed by more than 3 months, the dosing schedule should be restarted from the beginning to ensure optimal efficacy .
Safety and Tolerability of Inclisiran Dosing
Inclisiran has demonstrated a favorable safety profile across multiple studies and populations. Adverse events are generally mild or moderate, with injection site reactions being the most common. Serious adverse events are rare and occur at similar rates to placebo 2356+2 MORE. Long-term studies up to 4 years have shown that inclisiran remains well tolerated with no significant safety concerns, including no evidence of immunogenicity or adverse effects on platelets or immune markers 310.
Patient Adherence and Clinical Practice
The twice-yearly dosing schedule of inclisiran, after the initial and 3-month doses, is considered highly convenient and may improve patient adherence compared to therapies requiring more frequent administration. Dedicated clinics and team-based care models have been shown to further enhance adherence and facilitate monitoring for side effects 17.
Conclusion
Inclisiran is administered as a 300 mg subcutaneous injection at baseline, 3 months, and then every 6 months. This regimen provides sustained LDL cholesterol reduction, is well tolerated, and offers a convenient dosing schedule that supports patient adherence. If a dose is missed, specific protocols guide resumption or restarting of therapy to maintain efficacy. The long-term safety and effectiveness of this dosing approach have been confirmed in diverse patient populations.
Sources and full results
Most relevant research papers on this topic